- Home
- PASG vs ANTX Comparison
PASG vs ANTX Comparison
Compare PASG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- ANTX
- Stock Information
- Founded
- PASG 2017
- ANTX 2017
- Country
- PASG United States
- ANTX United States
- Employees
- PASG N/A
- ANTX N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- ANTX Health Care
- Exchange
- PASG Nasdaq
- ANTX Nasdaq
- Market Cap
- PASG 42.2M
- ANTX 37.6M
- IPO Year
- PASG 2020
- ANTX 2022
- Fundamental
- Price
- PASG $0.52
- ANTX $1.13
- Analyst Decision
- PASG Strong Buy
- ANTX Hold
- Analyst Count
- PASG 3
- ANTX 5
- Target Price
- PASG $8.00
- ANTX $3.50
- AVG Volume (30 Days)
- PASG 138.4K
- ANTX 149.8K
- Earning Date
- PASG 03-03-2025
- ANTX 03-27-2025
- Dividend Yield
- PASG N/A
- ANTX N/A
- EPS Growth
- PASG N/A
- ANTX N/A
- EPS
- PASG N/A
- ANTX N/A
- Revenue
- PASG N/A
- ANTX N/A
- Revenue This Year
- PASG N/A
- ANTX N/A
- Revenue Next Year
- PASG N/A
- ANTX N/A
- P/E Ratio
- PASG N/A
- ANTX N/A
- Revenue Growth
- PASG N/A
- ANTX N/A
- 52 Week Low
- PASG $0.45
- ANTX $0.87
- 52 Week High
- PASG $1.79
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- PASG 39.73
- ANTX 44.20
- Support Level
- PASG $0.52
- ANTX $1.09
- Resistance Level
- PASG $0.60
- ANTX $1.20
- Average True Range (ATR)
- PASG 0.05
- ANTX 0.05
- MACD
- PASG 0.00
- ANTX 0.01
- Stochastic Oscillator
- PASG 20.37
- ANTX 52.98
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.